Please login to the form below

Not currently logged in
Email:
Password:

Government urged to back life sciences

Emerging life sciences companies in the UK are finding it increasingly difficult to secure capital, according to the Bioindustry Association

Emerging life sciences companies in the UK are finding it increasingly difficult to secure capital, according to the Bioindustry Association (BIA). A survey of 295 companies revealed that the majority had found accessing finance a challenge during the past year and most of those seeking to raise equity had not obtained all the funds they required.

Clive Dix, chairman of the BIA, said: "In the current economic climate investors' risk appetite has declined dramatically even for relatively small sums of finance. This is having a significant impact on many of the small- and medium-sized enterprises in the life sciences sector."

According to Dix, government funding of up to £10m is needed to ensure the survival of therapeutic, diagnostic and devices companies. He believes that this would prove a worthwhile investment as the sector will play a significant role in helping the UK economy to grow post recession.

31st March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics